Drug Approval And Market OpportunityFDA approved THR-β agonist Rezdiffra (resmetirom) for NASH with moderate to advanced fibrosis, representing the first treatment of its kind and indicating a significant market opportunity.
Positive Payor And Prescriber DynamicsEarly payor coverage decisions for Rezdiffra are favorable with 30% commercial lives already covered, and market research indicates strong demand from prescribers, both promising signs for its commercial success.
Sales Forecast And Market PenetrationAnalyst models project robust sales, with FY24 estimates at $97M and peak sales reaching $4.9B by 2031, highlighting the strong commercial potential of Rezdiffra.